Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
23-valent pneumococcal polysaccharide vaccine Phase III in ≥2-year-olds
CTR20171552Phase 3Completed
- Sponsor
- Beijing Luzhu Biotechnology
- Start
- Dec 2017
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in Pneumococcal pneumonia (PP), pneumococcal meningitis, Pneumococcal Otitis Media, pneumococcal bacteremia, sponsored by Beijing Luzhu Biotechnology. Started Dec 2017; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
Pneumococcal pneumonia (PP)pneumococcal meningitisPneumococcal Otitis Mediapneumococcal bacteremia
Beyond the preview
Go deeper on CTR20171552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171552.